Cargando…

Factors Associated with Medical Follow-Up Adherence for Patients on All-Oral Regimen for Multidrug-Resistant Tuberculosis in Shenzhen, China

PURPOSE: The aim of this study is to identify factors affecting medical follow-up adherence of pulmonary multidrug-resistant tuberculosis (MDR-TB) patients on an all-oral regimen in Shenzhen, China to enhance intervention measures for increased treatment success. METHODS: A cohort study was conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hui, Zhang, Hailin, Xiong, Juan, Wang, Yi, Wang, Weiyu, Wang, Jingjing, Lin, Yi, Zhang, Peize
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275170/ https://www.ncbi.nlm.nih.gov/pubmed/34267504 http://dx.doi.org/10.2147/PPA.S316253

Ejemplares similares

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]
por: Fu, Liang, et al.
Publicado: (2023)

Clinical Evaluation of Active Tuberculosis-Related Deaths in Shenzhen, China: A Descriptive Study
por: Zhang, Peize, et al.
Publicado: (2021)

Duration and Determinants of Delayed Diagnosis with Tuberculosis in Shenzhen, China: A Cross-Sectional Study
por: Jiang, Youli, et al.
Publicado: (2022)

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States
por: Sinha, Pranay, et al.
Publicado: (2023)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Sleep quality and influencing factors and correlation with T-lymphocyte subpopulation counts in patients with pulmonary tuberculosis: a cross-sectional study
por: Zhang, Hailin, et al.
Publicado: (2022)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Non-adherence to anti-tuberculosis treatment among internal migrants with pulmonary tuberculosis in Shenzhen, China: a cross-sectional study
por: Tang, Ying, et al.
Publicado: (2015)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

An office building outbreak: the changing epidemiology of tuberculosis in Shenzhen, China
por: Guo, X. J., et al.
Publicado: (2020)

Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China
por: Fang, Mu-Tong, et al.
Publicado: (2021)

Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study
por: Lecai, Ji, et al.
Publicado: (2023)

Enzootic Angiostrongyliasis in Shenzhen, China
por: Zhang, Ren-Li, et al.
Publicado: (2008)

Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis
por: Liang, Juan, et al.
Publicado: (2021)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Closure of pulmonary cavity of a multidrug-resistant tuberculosis patient with catheter insertion – A case report
por: Zhang, Peize, et al.
Publicado: (2020)

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
por: Rich, M. L., et al.
Publicado: (2023)

Time-trend analysis of tuberculosis diagnosis in Shenzhen, China between 2011 and 2020
por: Hong, Chuang-Yue, et al.
Publicado: (2023)

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China
por: Xia, Hui, et al.
Publicado: (2020)

Grade III Severe QT Prolongation in an Indian Male on All-Oral Longer Regimen for Multidrug-Resistant Pulmonary Tuberculosis: World’s First Case
por: Yadav, Sankalp
Publicado: (2022)

Starting an All-Oral Longer Regimen in a Primary Multidrug-Resistant Pulmonary Tuberculosis Patient at a District Tuberculosis Center for the First Time: A Rare Case
por: Yadav, Sankalp
Publicado: (2022)

Challenges Faced by Multidrug-Resistant Tuberculosis Patients in Three Financially Affluent Chinese Cities
por: Zhang, Peize, et al.
Publicado: (2020)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

Tuberculosis infection in rural labor migrants in Shenzhen, China: Emerging challenge to tuberculosis control during urbanization
por: Li, Xiangwei, et al.
Publicado: (2017)

HPV Infections among MSM in Shenzhen, China
por: Zhang, Dong-Yan, et al.
Publicado: (2014)

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis
por: Jain, Kalpesh, et al.
Publicado: (2014)

Analysis of the sex ratio of reported gonorrhoea incidence in Shenzhen, China
por: Xiong, Mingzhou, et al.
Publicado: (2016)

HIV epidemics in Shenzhen and Chongqing, China
por: Yang, Shu, et al.
Publicado: (2018)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019–2020
por: Avaliani, Teona, et al.
Publicado: (2021)

Analysis of the economic burden of diagnosis and treatment on patients with tuberculosis in Bao’an district of Shenzhen City, China
por: Huang, Yixiang, et al.
Publicado: (2020)

How to strengthen clinical research in Shenzhen, China: qualitative study
por: Ji, Ping, et al.
Publicado: (2019)

Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment
por: Tierney, Dylan B., et al.
Publicado: (2014)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Adherence to Multidrug Resistant Tuberculosis Treatment and Case Management in Chongqing, China – A Mixed Method Research Study
por: Xing, Wei, et al.
Publicado: (2021)

Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China
por: Wang, Jing, et al.
Publicado: (2019)

Cardiac manifestations of COVID-19 in Shenzhen, China
por: Zeng, Jia-Hui, et al.
Publicado: (2020)

Willingness to seek medical care for tuberculosis and associated factors among the elderly population in Shenzhen: a cross-sectional study
por: Wang, Yunxia, et al.
Publicado: (2021)

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further
por: Udwadia, Zarir F, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_57dmnq811t73jmbkddrc9ociru